T3 Pharma wins prestigious Falling Walls Venture Award for its bacterial cancer therapy

Dr. Stefan von Holtzbrinck, Chairman of the Falling Walls Venture Jury and CEO of the Holtzbrinck Publishing Group, presents the "Science Start-Up of the Year 2018" award to Dr. Simon Ittig, CEO of T3 Pharma, and Christian Elias Schneider, Head Innovation and Entrepreneurship of the University of Basel. (Image: Falling Walls)

Our mission


T3 Pharmaceuticals is a pre-clinical biopharmaceutical company working to advance new generation therapies for cancer patients. Our dedicated team is developing highly specific and efficient treatments using live bacteria.
  • |